Human papillomavirus vaccination in the UK

BMJ

Volumn 337, Issue 7665, 2008, Pages 303-304

  Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; ADOLESCENT; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; MALE; MATHEMATICAL MODEL; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SQUAMOUS CELL CARCINOMA; UNITED KINGDOM; UTERINE CERVIX DYSPLASIA; VACCINATION; WART VIRUS; CHILD; METHODOLOGY; NOTE; VIRUS INFECTION;

ADOLESCENT; CHILD; FEMALE; GREAT BRITAIN; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 48349137472     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a842     Document Type: Editorial

References (13)

1. Department of Health. HPV vaccine recommended for NHS immunization programme. 2007. http://nds.coi.gov.uk/environment/fullDetail.asp?ReleaseID= 325799&NewsAreaID=2&NavigatedFromDepartment=True.
2. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
3. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine (in press).
4. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. Br J Obstet Gynaecol 2008; doi:10.1111/j.1471-0528.2008.01743.x.
5. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41.
6. Kim JJ, Andres-Beck B, Goldie SJ. Cost-effectiveness of vaccinating girls ages 10 to 26: implications of current US policy. 24th International Papillomavirus Conference and Clinical Workshop, Beijing, China 2007.
7. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915-23.
8. Newall AT, Beutels P, Wood JG, Edmunds WJ, Macintyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289-96.
9. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact ofvaccination against human papillomavirus infection and disease. Epidemiol Rev 2006;28:88-100.
10. Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008;336:1056-8.
11. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:308-20.
12. Kulasingam SL, Myers ER. Potential health and economic impact of addinga human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
13. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.